
Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimers DiseaseAward last edited on: 2/22/2019
Sponsored Program
SBIRAwarding Agency
NIH : NIATotal Award Amount
$225,000Award Phase
1Solicitation Topic Code
-----Principal Investigator
Shichun TuCompany Information
Allele Biotech and Pharmaceuticals (AKA: Allele Biotechnology and Pharmaceuticals)
6404 Nancy Ridge Drive
San Diego, CA 92121
San Diego, CA 92121
(858) 587-6645 |
oligo@allelebiotech.com |
www.allelebiotech.com |
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2016Phase I Amount
$225,000Public Health Relevance Statement:
Narrative Synaptic deficits mediated by oligomeric A? and hyperphosphorylated tau underlies cognitive decline in Alzheimer's disease (AD). In this project, we propose to develop biologics (nanoantibodies) targeting novel therapeutic target, RSP23RG1, to counteract AD-associated synaptic and cognitive impairments. The outcome of this study may lay a foundation for future development of therapeutic reagents in AD.
NIH Spending Category:
Acquired Cognitive Impairment; Aging; Alzheimer's Disease; Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD); Biotechnology; Brain Disorders; Dementia; Neurodegenerative; Neurosciences
Project Terms:
abeta oligomer; Abeta synthesis; abstracting; Accounting; Adenylate Cyclase; Adverse effects; Affinity; Agreement; Alleles; Alzheimer's Disease; Amyloid; Amyloid beta-Protein; amyloidogenesis; Animal Model; Animals; Antibodies; Antigens; Area; Autopsy; Behavioral Model; Binding; Brain; Budgets; Cell model; Clinical Trials; Cognition; Cognitive; Cognitive deficits; Conceptions; Consult; CREB1 gene; Cyclic AMP-Dependent Protein Kinases; Data; Dementia; design; Development; Disease; Elderly; experience; extracellular; Family; follow-up; Foundations; Funding; Future; G-Protein-Coupled Receptors; Generations; Genes; Genetic Engineering; Glycogen Synthase Kinase 3; Goals; Grant; Human; hyperphosphorylated tau; Immunization; immunogenicity; Immunoglobulin Fragments; Immunoglobulins; Impaired cognition; In Vitro; in vivo; induced pluripotent stem cell; innovation; Institutes; Integrins; Intellectual Property; interest; Joints; Lawyers; Learning; Legal patent; Ligands; Market Research; Mediating; meetings; Membrane; Memory; Memory impairment; Memory Loss; Messenger RNA; mouse model; Mus; neuron loss; Neurons; new therapeutic target; novel; novel therapeutics; oA?; Outcome Study; overexpression; Parkinson Disease; Pathogenesis; Pathway interactions; Patients; Pharmacologic Substance; Phase; phase 1 study; Phosphotransferases; Policies; preclinical study; professor; Property; Protein Biochemistry; Protein Engineering; protein expression; protein purification; Proteins; Publications; Reagent; receptor; Reporting; Research; Research Project Grants; research study; Role; screening; Secure; Senile Plaques; Serum; Severities; Signal Pathway; Small Business Innovation Research Grant; stem cell technology; Synapses; tau aggregation; tau phosphorylation; tau Proteins; tau-1; Technology; Testing; Therapeutic; therapeutic development; Therapeutic Human Experimentation; Therapeutic Studies; TimeLine; transcription factor; Transgenic Mice; United States National Institutes of Health; Veterans; Work
Phase II
Contract Number: ----------Start Date: ---- Completed: ----